Top Story

Amino acid peptide improves signs, symptoms in severe dry eye

May 22, 2015

Patients with chronic graft-vs.-host disease who were treated with thymosin β4 eye drops (RGN-259, 0.1%) experienced statistically significant improvements in signs and symptoms, according to a study published in Cornea.

Sosne and colleagues conducted a randomized, double-masked, placebo-controlled phase 2 clinical trial at two U.S. sites. Researchers treated nine men and women older than 18 years with severe dry eye with either Tβ4, a naturally occurring 43 amino acid peptide found in high concentrations in most tissues and cells, or placebo six times a day. The 56-day trial included a 28-day follow-up.

Publication Exclusive: Experts ponder drug compounding law’s impact on ophthalmology

May 26, 2015
In 2013, in the wake of infectious outbreaks traced to steroids and repackaged intravitreal Avastin produced at compounding pharmacies, Congress passed the Drug Quality…

NEI commits to develop noninvasive imaging technology

May 25, 2015
The National Eye Instituted announced that it will provide $3.8 million in 2015 and up to $17.9 million over the next 5 years to support five projects involving new…
VIDEO: Combination therapy better manages postop inflammation Meeting News CoverageVideo

VIDEO: Combination therapy better manages postop inflammation

May 25, 2015
MILAN — At the OSN Italy meeting, Luigi Fontana, MD, talks about postoperative management of inflammation after cataract surgery. In a single center randomized clinical…
Business News

Spark Therapeutics reports $2.3 million in revenue in first quarter

May 25, 2015
Spark Therapeutics, developer of SPK-RPE65, a potential gene therapy treatment for RPE65-mediated inherited retinal degenerations, reported $2.3 million in revenue in…
More News Headlines »
Agustin Gonzalez

BLOG: Keep your enemies close

April 28, 2015
Agustin L. Gonzalez, OD, FAAO, reminds us of the adage: “Keep your friends close, but your enemies…
More »